SSY Group (HKG:2005) said it has secured production and registration approvals from China's National Medical Products Administration for three drug products, according to a Monday Hong Kong bourse filing.

The approvals include Urapidil sustained-release capsules (30mg) for the treatment of essential and renal hypertension, pheochromocytoma-related hypertension, and urinary dysfunction linked to benign prostatic hyperplasia.

Approval was also granted for Nicardipine hydrochloride and sodium chloride injection (200ml), indicated for hypertensive emergencies and the management of abnormal hypertension during surgery.

In addition, the company received approval for Drotaverine hydrochloride injection (2ml), used to treat smooth muscle spasms caused by biliary and urinary tract diseases, gastrointestinal conditions, and dysmenorrhea.

Shares of the pharmaceutical firm were up nearly 2% at close of trade.